Dr. Erica Mayer -- ASCO 2014 | Dana-Farber Cancer Institute

Learn more about breast cancer treatment at Dana-Farber Cancer Institute: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce...

A pilot phase 2 clinical trial is testing the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer. The research was reported at the annual meeting of the American Society of Clinical Oncology (ASCO).